These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7726511)

  • 1. Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331.
    Hunter RL; Jagannath C; Tinkley A; Behling CA; Nolte F
    Antimicrob Agents Chemother; 1995 Feb; 39(2):435-9. PubMed ID: 7726511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice.
    Jagannath C; Emanuele MR; Hunter RL
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2898-903. PubMed ID: 10582879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
    Cai S; Sato K; Shimizu T; Yamabe S; Hiraki M; Sano C; Tomioka H
    J Antimicrob Chemother; 2006 Jan; 57(1):85-93. PubMed ID: 16303883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex.
    Shah LM; DeStefano MS; Cynamon MH
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2644-5. PubMed ID: 8913480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
    Huang CC; Wu MF; Chen HC; Huang WC
    J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium.
    Horgen L; Legrand E; Rastogi N
    Res Microbiol; 1997 Nov; 148(8):673-81. PubMed ID: 9765852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.
    Bakker-Woudenberg IA; van Vianen W; van Soolingen D; Verbrugh HA; van Agtmael MA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2387-98. PubMed ID: 15917538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
    Brown-Elliott BA; Philley JV; Griffith DE; Thakkar F; Wallace RJ
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
    Yajko DM; Sanders CA; Nassos PS; Hadley WK
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The absence of genetic markers for streptomycin and rifampicin resistance in Mycobacterium avium complex strains.
    Portillo-Gomez L; Nair J; Rouse DA; Morris SL
    J Antimicrob Chemother; 1995 Dec; 36(6):1049-53. PubMed ID: 8821605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of phenotypic and genotypic antibiotic susceptibility patterns in Mycobacterium avium complex.
    Wetzstein N; Kohl TA; Andres S; Schultze TG; Geil A; Kim E; Biciusca T; Hügel C; Hogardt M; Lehn A; Vehreschild MJGT; Wolf T; Niemann S; Maurer FP; Wichelhaus TA
    Int J Infect Dis; 2020 Apr; 93():320-328. PubMed ID: 32147539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
    Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
    J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    Sato K; Tomioka H; Akaki T; Kawahara S
    Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kwon BS; Kim MN; Sung H; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Park S; Shim TS; Chong YP; Jo KW
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex.
    Shah LM; Meyer SC; Cynamon MH
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2426-7. PubMed ID: 8891158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.
    Bermudez LE; Young LS; Inderlied CB
    Antimicrob Agents Chemother; 1994 May; 38(5):1200-2. PubMed ID: 8067766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an in vivo-mimic silkworm infection model with Mycobacterium avium complex.
    Yagi A; Yamazaki H; Terahara T; Yang T; Hamamoto H; Imada C; Tomoda H; Uchida R
    Drug Discov Ther; 2021 Jan; 14(6):287-295. PubMed ID: 33250497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
    Ito Y; Miwa S; Shirai M; Kanai M; Fujita K; Ohba H; Iwaizumi E; Oshima T; Kojima S; Suda T; Hayakawa H
    Respir Med; 2020 Aug; 169():106025. PubMed ID: 32442113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.
    Klemens SP; DeStefano MS; Cynamon MH
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2413-7. PubMed ID: 1336945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.